Experimental Standards: evaluating success in stem cell biology by Fagan, Melinda
1 
Experimental Standards: evaluating success in stem cell biology 
 
I. Experiments  
Experiments in scientific practice involve diverse components, lack clear boundaries, and bring 
new phenomena into existence.1  Their components include materials, technologies, protocols, 
concepts, human interventions, and standards for success.  Results are generated by elaborately 
contrived assemblages of heterogeneous ingredients.  But exhaustive inventory of these 
ingredients in any particular case is difficult.  Experiments do not have pre-established 
beginnings or ends.  Their boundaries are negotiable.  Practices of experimentation unfold at 
multiple spatio-temporal scales and diverse levels of social organization.  The latter range from 
individual investigators or small teams, to institutes, long-running collaborations, subfields 
dedicated to a particular model organism or technique, extending to research initiatives of 
national or international scope.  The results of experiments, at all these levels, are often new 
phenomena.  Novel products of experiment alter the landscape of possibilities considered in 
assessing evidential and relevance relations.  So experiments can transform both the world and 
our epistemic situation, via what Pickering calls the mangle of practice.’  
 These features, which make experiment an immensely productive way of gaining 
knowledge, also render it refractory to traditional methods of epistemic evaluation.  An 
experiment yields evidence for or against a hypothesis only within a specific context of 
materials, methods, background assumptions and epistemic values.  If the components and 
boundaries of experiments are in flux, and rapid generation of new results continuously alters the 
possibilities relevant for confirmation, then the relation of evidence to hypothesis is one of 
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ongoing mutual adjustment rather than test.  In fields driven by experiment, knowledge is 
produced by construction and alteration of experimental arrangements.  New phenomena 
produced by these experiments alter the space of possibilities, inducing conceptual, evidential 
and technological changes.  An experiment-driven field is, from the perspective of practice, a 
feed-forward system for producing new results, both abstract and material.   
 In particular cases, the ongoing mutual adjustment of experimental components, results, 
and hypotheses can be traced over time.  The result is thick epistemic history, describing patterns 
in a complex, continuously changing field of experimental practices.2  But on this approach, an 
evaluative or critical stance toward the field in question is difficult to ground.  One can describe 
changes in various aspects of experimental practice, at various levels of social organization.  For 
example, hypotheses in experiment-driven fields change rapidly, in response to new concepts 
and technologies as well as data.  Many view such changes as epistemic progress.  However, it is 
not obvious how to demonstrate this, if experimental arrangements, results and evidential 
standards are all undergoing transformation.  Our sense of progress might be illusory, an artifact 
of hope and hype.  More generally, though epistemic changes in experimental histories may be 
tracked and described, it is difficult to see how they can be evaluated without imposing 
philosophical assumptions on scientific practices.   
 This concern is particularly salient for the case of stem cell biology.  That field is typical 
of experimental life science today in its interdisciplinarity, rapid turnover of hypotheses, 
opportunistic use of technology, and paucity of formal theories or general laws.  But stem cell 
biology also has distinctive features that complicate the issue of epistemic evaluation.3  General 
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(i.e., non-technical) discussions of stem cell biology are dominated by themes of ‘hope and hype’ 
rather than ideals of truth, rationality or evidence.  Stem cell biologists loudly and unabashedly 
proclaim their ambitions for a revolution in medicine, scientific stardom and profitable 
associations with industry.  Ethical controversies, playing out differently in different national 
contexts, create a patchy landscape of political, bioethical and financial restrictions, which 
scientists must navigate to perform experiments at all.  In this welter of socio-politcal values, 
epistemic considerations recede into the background, relegated to the esoteric workings of lab 
benches and the occasional unsettling production, such as human embryonic stem cells or Dolly 
the sheep.  
 This paper aims to bring the epistemic dimensions of stem cell experiments out of the 
background, and show that they can be critically evaluated.  After introducing some basic 
concepts of stem cell biology, I set out the current “gold standard” for experimental success in 
that field (§2).  I then trace the origin of this standard to a 1988 controversy over blood stem cells 
(§3).  Understanding the outcome of this controversy requires attention to the details of 
experimental techniques, the organization of epistemic communities, and relations between the 
two (§4).  With its resolution, a standard for experimental success was established for HSC 
research, which in turn serves as an exemplar for studies of other stem cells.  This historical case 
study reveals a robust standard for experimental success in stem cell biology: to trace processes 
of development at the single-cell level, in the form of cell lineage hierarchies.  Experiments 
conforming to this standard can be further critically assessed as means to the therapeutic end of 
stem cell research: use of stem cells to repair human organs and tissues.   
 
2. Stem cells and “gold standards”  
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Stem cells are self-renewing sources for organismal development at the cellular level.  They are 
defined by two capacities pertaining to cell division.  The first is self-renewal: long-term 
production of more cells of the same type.  The second is differentiation: production of more 
specialized cell types.  The organs and tissues of multicellular organisms are composed of the 
differentiated descendents of stem cells.  Small numbers of tissue-specific stem cells also persist 
at various sites in the adult organism, including skin, gut, bone marrow, muscle, and brain.  
These ‘adult stem cells’ function as storehouses for cell renewal in specific organs or tissues.  
Their pathological counterparts are cancer stem cells, the source cells that grow and multiply 
tumors, caricatures of organs.4  Embryonic and fetal stem cells are artifacts of cell culture, the 
clonal descendants of cells extracted from organisms in early stages of development (as their 
monikers suggest) and cultured in vitro.  Embryonic stem cells exist as cultured cell lines; they 
have no directly corresponding in vivo counterparts.  A more recent artifact, the induced 
pluripotent stem cell, is the result of ‘reprogramming:’ introduction of genetic regulatory factors 
into an adult somatic cell, which induce a phenotype similar to that of an embryonic stem cell.    
 The above classifications are unlikely to stay fixed, but do indicate the present contours 
of the field of stem cell biology.  Its two main branches are concerned, respectively, with adult 
and embryonic stem cells.  The former are found in vivo, are difficult to culture outside the body, 
and exhibit limited self-renewal and differentiation potential.  The latter are grown in culture, 
where they exhibit unlimited self-renewal and very broad differentiation potential.  In light of 
these contrasts, it is unsurprising that the two branches of stem cell biology endorse different 
“gold standards” for experiments.  The gold standard for embryonic stem cell research (now 
including research on induced pluripotent stem cells) is to create a cell line with the same 
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molecular features and cellular capacities as those of ‘canonical’ cultured embryonic cell lines  
The cellular capacities are unlimited cell division (self-renewal) and differentiation into all cell 
types of the adult organism (pluripotency); the molecular features are incompletely 
characterized.5  In contrast, the gold standard for adult stem cell research is to extract cells from 
an adult organ or tissue, select the stem cells in the tissue using surface markers, transplant one 
cell immediately into a host animal, and observe self-renewal and reconstitution of the relevant 
tissue, organ, or cell type, for the lifespan of the animal.6  More briefly: the avowed gold 
standard for embryonic stem cell research is creation of an artifact with certain (not-fully 
determined) features; while in adult stem cell research it is a method culminating in regeneration 
of some part of an animal.   
 Due to their demonstrated in vivo efficacy, adult rather than embryonic stem cells are the 
model of experimental success in the field.  More specifically, the in vivo efficacy of one type of 
adult stem cell, the blood-forming or hematopoietic stem cell, is a model of experimental 
success.  Blood stem cells (HSC) were the first non-cancerous mammalian stem cells to be 
isolated, and the first characterized at the molecular level.  Until very recently, HSC were the 
only stem cells used in routine clinical practice, comprising the active ingredient, so to speak, in 
bone marrow transplantation.  Though not the stem cells from which most is hoped, blood stem 
cells are our current exemplar of stem cells in use.  The origins of the current gold standard for 
adult stem cell research, and the standard for experimental success in stem cell biology as a 
whole, are in HSC research.  As per usual in biomedicine, research on human HSC was preceded 
by research on inbred mice.  So, with regard to experimental success, mouse HSC research is the 
stem of stem cell biology.  
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3. History in the blood7  
Blood stem cell research began in the 1960s as an offshoot of radiation research, itself a response 
to developments in 20th century physics that culminated in the Manhattan Project.8  In the 1950s, 
researchers in the US and UK discovered that mice given lethal doses of γ-radiation survive if 
injected with bone marrow cells from a donor of the same inbred strain.  One side-effect of 
‘radiation rescue’ was the appearance of bumps, or nodules, on the spleens of transplant 
recipients.  In the early 1960s, Canadian researchers discovered that splenic nodules contained 
diverse blood cells (red blood cells, granulocytes, macrophages, lymphocytes) all descended 
from a single donor cell – each nodule was a clone, or colony.  HSC were operationally defined 
as spleen colony-forming cells.  Scientists then began to design experiments to isolate and 
characterize this elusive cell type from mouse bone marrow.  
In the late 1980s, two groups claimed to have accomplished this goal: a research team of 
five from the Radiobiological Institute in Rijswijk, the Netherlands, led by Jan Visser (in 1984) 
and three members of Irv Weissman’s lab at Stanford University Medical Center in California (in 
1988). The two reports describe similar methods consisting of three steps: cell sorting, functional 
assays and microscopic observation.  In the first step, bone marrow cells are sorted into 
populations (‘subsets’) by size, density, and surface phenotype.  Two technical innovations of the 
1970s , monoclonal antibodies and fluorescence-activated cell sorting, allowed single cells to be 
sorted into discrete subpopulations according to expression of specific surface molecules.  Next, 
these subpopulations are assayed for HSC capacities.  Three types of assay are described: in vitro 
cell culture, which realizes differentiation potential for a specific cell type; spleen colony 
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formation after transplantation, which indicates self-renewal and multipotency; and ‘radiation 
rescue’ of irradiated hosts, which realizes the capacity for full immune reconstitution 
(multipotency).  In the third and final step, cell populations with increased HSC capacities 
relative to normal bone marrow are examined by EM and light microscopy.  The end result is a 
cell population with known physical, surface, morphological and histological characteristics, 
exhibiting a quantifiable degree of HSC function.  Both groups argued that their method yielded 
all and only HSC.9   
Despite the overall similarities, there were differences in the details.  Each method used 
one distinctive purification step, different surface molecules for cell sorting, and, most 
importantly, different standards to estimate HSC purification.  The Rijswijk group calculated this 
quantity in terms of spleen colony-forming units, a modification of the original method for 
detecting HSC in mouse spleens.  The Stanford group, in contrast, used the rate of whole-animal 
radiation rescue as the standard, focusing on the in vivo effect that initiated the entire line of 
research.  Because of these differences, the two results were not directly comparable.   
Yet scientists did compare them.  Controversy ensued immediately upon publication of 
the 1988 report.  The next issue of Immunology Today featured an openly skeptical editorial:   
 
But does this represent any advance on previously published data?  Are these the 
real stem cells?  Does the report merit its widespread coverage in the newspapers 
or is this yet another example of indiscriminate glamourization by some sections 
of the press?10 
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Despite these concerns, the balance of scientific opinion eventually favored the 1988 report. 
Widely cited (1581), it is counted among 20 major “turning points in modern immunology.” 11 
Generalization of its method is currently the “most rigorous assessment” of adult stem cell 
characteristics.12  Its first author contributed the chapter on isolation and characterization of HSC 
in the main textbook of stem cell biology; its last author is currently the President of the 
International Society for Stem Cell Research.  The 1984 report, though respected among blood 
cell specialists, has had much less impact (cited 107 times).13 
 
4. Establishing standards 
The fame of the Stanford paper is puzzling, since two reports describe similar methods and claim 
the same result.  Neither was retracted or dismissed; and they do not contradict one another.  
Moreover, the 1984 paper had priority, by a four-year margin.  The normal “priority rule” that 
the first publication of a scientific result receives the preponderance of credit was clearly violated 
in this case.   
 The differential impact would not be surprising if there had been, at some point between 
1988 and the present day, a consensus of HSC researchers that 1988 method yielded “the real 
stem cells” while the 1984 method did not.  But there was no such consensus.  Instead, within a 
year, there was broad agreement in the HSC community (including the Rijswijk and Stanford 
groups) that neither method yielded all and only HSC.  This ‘negative consensus’ has persisted 
for thirty years, robust to all the technological advances and experimental refinements during that 
interval: There is no widely agreed-upon procedure for isolating all and only HSC.  So, mere 
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months after the HSC controversy began, it was over.  A consensus, including the Stanford and 
Rijswijk groups, emerged that neither method yielded “the real stem cells,” but a mixture of 
HSC and blood progenitor cells. 14 
 Sociological factors are another possible explanation for the outcome of the HSC 
episode.  The 1984 paper was published in the Journal of Experimental Medicine, the 1988 paper 
in Science – a more prestigious and widely read journal.  Furthermore, Weissman drew 
additional attention to his result by holding a press conference, while the Rijswijk group did not 
alert the media.  It is possible that the relative prestige of US and European science, or of the 
types of institutions involved, contributed to the difference.  Determining which, if any, of these 
prima facie plausible explanations is correct is a task for empirical sociologists.  My concern is 
not to show that one or another sociological explanation of the HSC episode is correct, but to 
show that, whatever sociological factors were in play, experimental methods and results also 
played a crucial role.  The implications of a purely sociological explanation are unwelcome.  If 
experimental methods and results did not play a decisive role in the establishment of stem cell 
biology’s standards of experimental success, then the drivers of stem cell research are merely 
hope, hype and media attention.  The HSC case cannot be dismissed as atypical or minor.  As 
noted above, it provides the exemplar or model for isolation of other stem cells, setting the 
current standard in stem cell biology.  The HSC episode was a turning point in the development 
of those standards.   
 A more satisfactory understanding of the HSC case emerges if we consider how each of 
the two groups participated in its wider scientific community.  The Rijswijk group belonged to a 
community of medically-trained hematologists (blood cell experts), the Stanford group to the 
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rising community of cellular immunology (experts on cells of the immune system).  The 
hematologists formed a global network with centers in Toronto, Melbourne, Rijswijk, 
Manchester, and the Eastern US.  Beginning with the spleen colony assay, these centers 
‘differentiated:’ inventing new assays, variations on the original spleen colony theme.  There was 
a division of labor among them.  From the late 1960s, the role of the Rijswijk group was to 
isolate HSC.  Other groups focused on the specific blood cell lineages, the biochemistry of 
regulatory factors in blood cell development, and the concept of a stem cell niche.   
The Rijswijk group used a classic hematological approach: classify bone marrow cells 
into ‘subsets’ using “well-defined” cell properties (size, density, morphology, surface molecules, 
and more or less sensitivity to a given drug), then localize HSC to one ‘subset.’  They focused on 
physical and chemical properties of bone marrow cells, using classic methods of cell biology 
(density centrifugation and electron microscopy) to distinguish cell types.  New technologies 
were added to existing techniques as they became commercially available.  But the basic strategy 
remained the same: systematically survey the published literature for ways of non-lethally 
tagging blood cells, and test every available antibody or chemical marker for correlation with 
increased spleen colony formation.  It was a lucid approach: all cells have some size, density, 
morphology, surface phenotype, and more or less sensitivity to a given drug.  The trick was to 
find what combination of these general cell properties correlated with the ability to form spleen 
colonies.  The markers themselves, however, were diverse, based on general properties of cells 
and available biochemical tags.  Visser et al’s ever-lengthening protocol for isolating HSC was 
the concatenation of fortuitous discoveries gleaned from the wider community.  Their key 
bioassays measured colony-formation in spleen and on agar.  In the late 1970s and early 1980s, 
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this standard for measuring HSC function was increasingly questioned in the wider community 
of hematologists. 
 So the Rijswijk group’s standard diverged from that of the wider HSC community.  This 
occurred because that community was differentiated with respect to its methods.  This diversity, 
along with geographic distance, made coordination of results difficult.  Rijswijk’s functional 
assays were specific to Rijswijk.  Elsewhere, however, hematologists were fitting their diverse 
results together, however, and coming up with unsatisfying results.  As early as 1974, 
hematologists had questioned the identification of HSC with spleen colony-forming cells, due to 
inconsistencies in results from different laboratories.  Gradually, the simple identification of 
HSC with spleen colony-forming cells was replaced with a “three-tiered model” of HSC, 
lineage-committed progenitor cells, and mature blood cells.  Colony-forming cells could be the 
first, second or a mixture of the two, depending on experimental conditions.  Once recognized as 
an ambiguous indicator of HSC, spleen colony-formation was replaced by a new defining 
standard: radiation rescue of cell transplant recipients.  But the shift was slow and uneven, 
because the hematological community shared little beyond an interest in blood cells and a 
historical tie to the spleen colony assay.  The Rijswijk group retained the old standard later than 
most.    
The Stanford group participated in the immunology community in a quite different way.  
They were part of a large laboratory, which formed its own community within the larger context 
of cellular immunology.  In the 1970s, there were two distinct immunology communities at 
Stanford’s Medical Center: one biochemical, focused on Ab-Ag binding; the other investigating 
immune cells and genetics.  The latter community was closely knit by formal and informal 
discussion groups, which fostered interactions between diverse laboratories and departments. 
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Stanford was a major center for immunology, and regular visits by prominent researchers linked 
it with the wider international field.  Within this disciplinary context, the Weissman laboratory 
was distinguished by an emphasis on immune cell development, but not unified by a single aim 
or technique. The majority of members studied the development of immune function in cells 
from diverse lymphoid organs (blood, thymus, lymph nodes) using various methods (molecular 
genetics, biochemistry, cell biology, surgery, developmental biology).  Collaborations emerged 
in situ, and were encouraged both within and outside the laboratory.   
The Weissman lab did, however, have a strong methodological norm: to work with single 
cells or pure cell populations, emulating biochemical rigor.  Assays that worked at the single cell 
level were the standard for in vitro functional assays, cell sorting, and in vivo radiation rescue.  
This ‘single-cell’ standard was consistent with wider community norms in immunology.  
Working to this standard, members of the Weissman lab collaborated with one another, and with 
other immunology groups, to work out developmental pathways for immune cells.  In the mid-
1980s, three of these lineage projects converged on a single cell population. A striking 
experimental result, produced by post-docs sharing materials from their different projects, knit 
these previously distinct lines of inquiry into a single coordinated search for the blood stem cell.  
Further collaborations within the laboratory, with other Stanford groups, and with a West 
German immunology lab, yielded a new experimental arrangement in 1988.  Though the 
controversial report had only three authors, its result emerged from decades of experimental 
work by dozens of researchers at Stanford and beyond.   
The outcome of the HSC controversy can now be explained.  Both groups used similar 
methods to isolate cells they identified as HSC.  But the two methods involved different forms of 
participation in a wider epistemic community.  The Stanford group was a center of continuous, 
13 
cumulative collaboration aimed at understanding interrelated pathways of immune cell 
development at the single-cell level.  The 1988 method was a specific refinement of a general 
method deployed throughout this collaborative network.  The Rijswijk group, in contrast, 
interacted with the widely-distributed hematology community only to gather sorting criteria for 
bone marrow cells into ‘subsets;’ their ‘downstream’ method and standards were local.   
The community perspective brings out a further contrast: the two methods implicitly 
describe different models of HSC. The model in the Rijswijk method (so to speak) was a 
cytophysical profile of colony-forming cells, correlating a complex of properties (size, density, 
morphology, surface phenotype, drug-sensitivity) with HSC capacities.  But these criteria were 
based on general properties of cells and available biochemical tags; a concatenation of fortuitous 
discoveries gleaned from the wider community.  The cell population profiled in this way was 
linked to HSC only via functional assays increasingly viewed as ambiguous in the field.  In 
contrast, the model in the Stanford method is of blood cell development.  The Weissman group’s 
markers tracked what was then known about developmental pathways in different blood cell 
lineages, and related these to the HSC surface phenotype.  By focusing on single cells in this 
coordinated system of bioassays, they characterized HSC as the unique stem of a unified model 
of blood cell development.   
The Weissman group’s model conformed to and elaborated the three-level hierarchy 
widely-accepted in the hematology community at the time.  This allowed the two communities to 
merge, establishing single-cell assays and reconstitution of animal parts (i.e., the immune 
system) as the gold standard for HSC research.  Experiments conforming to this standard further 
elaborated the cell lineage hierarchy stemming from HSC.  This was a collective enterprise, 
undertaken not by a single research team or lab but by an inclusive experimenting community.  
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The new, expanded HSC community had ties to both predecessors.  Visser and Weissman helped 
constitute it, traveling worldwide to argue for their groups’ respective methods before audiences 
of blood and immune cell experts.  Groups investigating HSC with new tools of molecular 
biology critiqued both methods.  All this led to the eventual consensus that HSC had not yet been 
isolated.  Various groups (including those at Rijswijk and Stanford) began working to 
characterize more finely-grained cell populations from mammalian bone marrow.   
Though both groups contributed to the new consensus, it was the Weissman group’s 
method, and the hierarchical model of cell development implicit within it, which provided the 
standard for HSC research.  And this model and method were quickly extrapolated to other 
experimental studies of stem cells: from mouse to human HSC, from blood to brain, gut, skin, 
muscle, liver, pancreas, the enteric nervous system, from normal to cancerous development 
(leukemia, colon cancer, breast cancer, prostate cancer).  HSC served as an exemplar and a basis 
for comparison – a model system.  The basic method was adapted, with numerous alterations, to 
each new experimental context.  Results from other systems in turn ‘fed back’ to further refine 
the HSC model, further elaborating the simple three-level hierarchy to an intricately-tiered 
structure of lineages.  This process was well underway when human embryonic stem cells were 
created in 1998.  The epistemic community of adult stem cell research grew as a reticulated 
network of experimental models and methods, linked by complex relations of similarity and 
difference to one another and to embryonic stem cells.  But in all this variety and revision, there 
is a robust standard for experimental success: trace processes of development at the single-cell 
level, in the form of cell lineage hierarchies.   
 
5. Evaluating experiments   
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Experiments in stem cell biology can be critiqued in terms of this robust standard.  Moreover, the 
field’s therapeutic aim adds another evaluative dimension.  The clinical aim of stem cell biology 
is to cure injuries and pathological conditions by introducing cells or cell products into human 
bodies.   The robust experimental standard discussed above suits this aim.  Experiments that 
meet it contribute to hierarchical models of cell development that predict the pathways taken by 
single cells.  But it is not enough that experimental methods and results mesh with our aspirations 
and hopes.  The therapeutic aim of stem cell research gives particular significance to predictions 
about what cells will do when let loose in human bodies.  It is these hypotheses which most need 
critical evaluation.  Before using experimentally-based models of cell development to predict the 
effects of cells in vivo, it is crucial to distinguish between features of these models that reflect 
our interventions or aspirations, and those that reflect ‘cell intrinsic’ pathways or stable features 
of physiological environments.  Close attention to experimental methods is required to make this 
distinction.  So critical evaluation of experiments in stem cell biology must attend to the details 
of experimental practice.  But the case study above narrows the focus of this attention 
considerably.  Experiments can be evaluated for fit with the robust single-cell standard, and as 
means to the therapeutic end of cell therapy.  Though stem cell biology remains in flux, with new 
standards grounded in systems biology now becoming established, the HSC case shows that 
criticism of experiments in stem cell biology is possible.  Its results provide a starting point from 
which to explicate additional standards and norms, as the field continues to transform itself.   
 
6. Summary and conclusion  
Several features of experiment problematize epistemic evaluation: diverse components, unclear 
boundaries, and transformative potential.  This paper has shown how to gain critical purchase on 
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an experimental field which exhibits these features to a high degree: stem cell biology.  A 
historical approach emphasizing the details of experimental methods, organization of epistemic 
communities, and relations between the two, reveals a robust standard for experimental success 
in stem cell biology: delineate hierarchies of development at the single cell level.  This critical 
historical approach, including future hopes and clinical values, reveals stable standards for 
evaluating experiments in stem cell biology which are grounded in scientific practice rather than 
philosophical assumptions.  Since stem cell biology is a hard case (§2), this critical approach 
should apply to other experiment-driven sciences as well, though the specific standards 
explicated here likely will not.   
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